Press Releases

GW Welcomes Move by UK Regulator to Provide More Information for Sativex® Prescribers

13 December 2008

GW Pharmaceuticals plc (AIM: GWP) welcomes the publication today by the UK regulator, the Medicines & Healthcare products Regulatory Agency (MHRA) of a Public Information Report on Sativex®, GW’s cann... more

Preliminary Results for the Year Ended 30 September 2008

18 November 2008

GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex, announces its preliminary results for the year ended 30 September 2008. ... more

Sativex® Phase III MS Spasticity Study Completes Patient Recruitment

1 October 2008

GW Pharmaceuticals plc (GWP:AIM) announces that it has completed patient recruitment into its Sativex® Phase III MS Spasticity trial. This trial was requested by the UK regulator prior to obtaining ap... more

Interim Results For The Six Months Ended 31 March 2008

19 June 2008

GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its interim results for the six months ended 31 March 2008. ... more

Notification of Results

5 June 2008

GW Pharmaceuticals plc (AIM: GWP) will be announcing its interim financial results for the six months ended 31 March 2008 on Thursday 19 Jun... more

Phase III MS Neuropathic Pain Trial Preliminary Results

8 April 2008

GW Pharmaceuticals plc (AIM: GWP) announces preliminary results of a Phase III double-blind randomised placebo-controlled study of Sativex® in 339 patients with central neuropathic pain due to Multipl... more

Catalan Government Reports Positive Outcome of Sativex Access Programme

4 April 2008

GW Pharmaceuticals plc (GWP:AIM) announces that the Government of Catalonia in Spain is today publishing positive results of its pilot programme to evaluate Sativex® as a treatment for high need patie... more

AGM Statement

18 March 2008

Dr. Geoffrey Guy, Chairman of GW Pharmaceuticals plc, will make the following comments at today’s Annual General Meeting:... more

Appointment of Company Secretary

5 March 2008

GW Pharmaceuticals plc announces that Adam George BSc, ACA has been appointed as Company Secretary and Financial Controller.... more

Preliminary Results for the Year Ended 30 September 2007

22 January 2008

GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines including Sativex®, announces its preliminary results for the year ended 30 September 2007.... more

Highly Promising Results for New GW Cannabinoid Treatments for Diabetes and Related Metabolic Disorders

22 January 2008

GW Pharmaceuticals plc (AIM: GWP) announces that it has generated highly promising results in both pre-clinical pharmacology studies and a Phase I trial of a new potential cannabinoid treatment for ty... more